Which peptides will the FDA propose adding to the 503A Bulks List?
Trade ↗BPC-157 is favored at 95% as of 24 Oct 2026, 14:37 UTC across 7 markets.
- BPC-157: 95% (24h change 0%)
- KPV: 90% (24h change 0%)
- Epitalon: 79% (24h change 0%)
- Semax: 79% (24h change 0%)
- TB-500: 71% (24h change 0%)
- MOTS-c: 71% (24h change 0%)
- Emideltide: 29% (24h change 0%)
About this market
Market question: Which peptides will the FDA propose adding to the 503A Bulks List?
How to read these odds
Each percentage is the latest traded Kalshi price for that option. A 62% contract price implies a 62% market-estimated chance, but prediction markets can move quickly and are not polls.
Market odds FAQ
Who is favored in Which peptides will the FDA propose adding to the 503A Bulks List?
BPC-157 is favored at 95% as of 24 Oct 2026, 14:37 UTC, based on live Kalshi prediction-market prices.
What are the current odds for Which peptides will the FDA propose adding to the 503A Bulks List?
BPC-157: 95%; KPV: 90%; Epitalon: 79%; Semax: 79%; TB-500: 71%; MOTS-c: 71%. These are live market prices.
Where do these odds come from?
Each probability is a traded price from Kalshi, a CFTC-regulated prediction-market exchange. A contract trading at 62¢ implies a 62% market-estimated chance. ElectionOdds displays the data and does not create its own forecast.